Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Current Assets (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Current Assets readings, the most recent being $290.2 million for Q1 2026.

  • Quarterly Current Assets rose 37.27% to $290.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $290.2 million through Mar 2026, up 37.27% year-over-year, with the annual reading at $288.5 million for FY2025, 10.0% up from the prior year.
  • Current Assets hit $290.2 million in Q1 2026 for Oric Pharmaceuticals, up from $288.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $324.1 million in Q1 2024 and bottomed at $193.2 million in Q1 2023.
  • Average Current Assets over 5 years is $254.4 million, with a median of $262.2 million recorded in 2024.
  • The largest annual shift saw Current Assets soared 67.78% in 2024 before it plummeted 34.76% in 2025.
  • Oric Pharmaceuticals' Current Assets stood at $210.5 million in 2022, then rose by 1.02% to $212.6 million in 2023, then grew by 23.36% to $262.2 million in 2024, then increased by 10.0% to $288.5 million in 2025, then grew by 0.61% to $290.2 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Current Assets are $290.2 million (Q1 2026), $288.5 million (Q4 2025), and $295.6 million (Q3 2025).